Bishop Museum welcomes three new manatees for rehabilitation
BRADENTON, Fla. (WFLA) — The Bishop Museum of Science and Nature welcomed three new manatees on Tuesday.
The arrival of the three young female manatees, named Mandalore, Crane and Kyber, marks the next phase in their recovery and rehabilitation process.
Mandalore, an orphaned calf, was rescued from Orange City in February weighing 180 pounds. She is now 320 pounds.
Kyber, an orphaned calf rescued from Crystal River, suffered from prolonged exposure to cold water. She originally weighed in at 200 pounds and is now up to 310 pounds.
Crane, rescued from Crane's Bayou, is recovering from cold stress syndrome. At the time of her rescue, she weighed 355 pounds and is now up to 450 pounds.
'It is important that the manatees feel comfortable in their new environment,' said Virginia Edmonds, director of animal care at The Bishop. 'We give them every consideration that you would to a human who is adjusting to a major change in their life. The ability to thrive and meet growth milestones equates to a timely return to the wild.'
The three young manatees are currently acclimating to their temporary environment at the Rehabilitation Habitat. Those who wish to observe them can visit The Bishop and learn about the challenges they face on their road to recovery.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
a few seconds ago
- Medscape
Raynaud Phenomenon Tied to Elevated Cardiovascular Risk
TOPLINE: Individuals with Raynaud phenomenon without underlying systemic autoimmune rheumatic diseases had higher risks for major adverse cardiovascular events (MACE) and venous thromboembolism than did a comparator group with irritable bowel syndrome (IBS), regardless of age. METHODOLOGY: Researchers conducted a retrospective cohort study to examine whether individuals with Raynaud phenomenon experienced cardiovascular outcomes more frequently than those without the condition. They included 30,088 individuals younger than 45 years and 60,145 aged 45 years or older with Raynaud phenomenon without systemic autoimmune rheumatic diseases , identified from electronic health records of centers in North America between March 2005 and March 2025. An equal number of propensity score-matched individuals with IBS were assigned as comparators to both age categories. The researchers chose IBS as a comparator group because, like Reynaud phenomenon, it is common in younger and female individuals. In addition, it is not known to be associated with adverse cardiovascular outcomes. Co-primary outcomes were MACE and venous thromboembolism, evaluated over mean follow-up durations of 4.4-4.9 years across groups. TAKEAWAY: Among individuals younger than 45 years, those with Raynaud phenomenon had higher risks for MACE (hazard ratio [HR], 1.23; 95% CI, 1.07-1.42) and venous thromboembolism (HR, 1.32; 95% CI, 1.20-1.46) than did those with IBS. Similar results were observed among individuals aged 45 years or older, where those with Raynaud phenomenon had higher risks for MACE (HR, 1.17; 95% CI, 1.13-1.20) and venous thromboembolism (HR, 1.20; 95% CI, 1.14-1.26) than those with IBS. Individuals with Raynaud phenomenon had higher risks for secondary outcomes such as stroke, any cardiovascular disease, and pulmonary embolism noted in both age categories. IN PRACTICE: '[This] data substantiates several previous reports of an increased risk of CVD [cardiovascular disease] in individuals with RP [Raynaud phenomenon], and provides further supporting evidence of a similar risk of VTE [venous thromboembolism],' the authors of the study wrote. 'Taken together our findings lend further support to suggest that RP (in the absence of any secondary SARD [systemic autoimmune rheumatic disease]) could be a manifestation of subclinical CVD. Of course, this requires further confirmation including prospective studies,' they added. SOURCE: This study was led by Michael Hughes, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom. It was published online on August 5, 2025, in Seminars in Arthritis and Rheumatism. LIMITATIONS: Diagnostic codes were used for identifying the conditions; however, misclassification bias may be possible. Details such as digital ischemic episodes were not available for individuals with Raynaud phenomenon and age of onset and family history were not assessed. Many oral drug treatments for Raynaud phenomenon are vasodilators also used for systemic hypertension; hence, the primary indication was unclear. DISCLOSURES: One author reported receiving support from the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre. Another author reported receiving support from NIHR Clinical Lectureship, and working at centers supported by Versus Arthritis and NIHR Manchester Biomedical Research Centre. Two authors reported receiving research funding, speaker fees, honoraria, and consultancy fees and having other financial ties with multiple companies including Janssen, Sanofi, and Novartis. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
CNN
2 minutes ago
- CNN
Rabbits with ‘horns' in Colorado are being called ‘Frankenstein bunnies.' Here's why
A group of rabbits in Colorado with grotesque, hornlike growths may seem straight out of a low-budget horror film, but scientists say there's no reason to be spooked — the furry creatures merely have a relatively common virus. The cottontails recently spotted in Fort Collins are infected with the mostly harmless Shope papillomavirus, which causes wart-like growths that protrude from their faces like metastasizing horns. Viral photos have inspired a fluffle of unflattering nicknames, including 'Frankenstein bunnies,' 'demon rabbits,' and 'zombie rabbits.' But their affliction is nothing new, with the virus inspiring ancient folklore and fueling scientific research nearly 100 years ago. The virus likely influenced the centuries-old jackalope myth in North America, which told of a rabbit with antlers or horns, among other animal variations. The disease in rabbits also contributed to scientists' knowledge about the connection between viruses and cancer, such as the human papillomavirus that causes cervical cancer. The virus in rabbits was named after Dr. Richard E Shope, a professor at The Rockefeller University who discovered the disease in cottontails in the 1930s. News about the rabbit sightings in Fort Collins, 65 miles (105 kilometers) north of Denver, started getting attention after residents started spotting them around town and posting pictures. Kara Van Hoose, a spokesperson for Colorado Parks and Wildlife, told The Associated Press on Wednesday that the agency has been getting calls about the rabbits seen in Fort Collins. But she said that it's not uncommon to see infected rabbits, especially in the summer, when the fleas and ticks that spread the virus are most active. The virus can spread from rabbit to rabbit but not to other species, including humans and pets, she said. The growths resemble warts but can look like horns if they grow longer, Van Hoose said. The growths don't harm rabbits unless they grow on their eyes or mouths and interfere with eating. Rabbits' immune systems are able to fight the virus and, once they do, the growths will disappear, she said.
Yahoo
35 minutes ago
- Yahoo
Are Wall Street Analysts Predicting Danaher Stock Will Climb or Sink?
Science and technology company Danaher Corporation (DHR), headquartered in Washington, D.C., designs, manufactures, and markets innovative products and services in the fields of life sciences, diagnostics, and biotechnology. The company operates through three broad segments: Biotechnology, Life Sciences, and Diagnostics. With a market capitalization of $147.31 billion, Danaher's offerings are used in research labs, hospitals, and industrial settings to advance scientific discovery, improve patient care, and ensure water quality and food safety. Shares of this medical technology company have declined by 22.2% over the past 52 weeks, as the company experiences a slowdown in its performance. More News from Barchart Why This Cannabis Penny Stock Could Be Wall Street's Next Meme Trade Breakout Apple Stock Is Gaining Momentum, Is AAPL Stock a Buy? Peter Thiel-Backed Bullish Is About to IPO. Should You Buy BLSH Stock? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For comparison, the broader S&P 500 Index ($SPX) has gained 19% over the same period. This year, Danaher's stock price has declined by 8.9% year-to-date (YTD), while the S&P 500 index has increased by almost 10%. Taking a closer look, Danaher's shares have also been underperforming the sector-specific Robo Global Healthcare Technology and Innovation ETF (HTEC), which has gained 5.2% over the past 52 weeks and 4.7% YTD. For the fiscal year 2024, Danaher's topline declined marginally year-over-year (YOY). While the company's weak price action has coincided with an annual topline slowdown, its recent quarterly financials came in better than expected, sparking a 4.2% surge in its share on Jul. 23. For the second quarter of fiscal 2025, its sales increased by 3.4% YOY to $5.94 billion, which was better than the $5.84 billion that Wall Street analysts were expecting. At the heart of this growth was the Danaher Business System, along with gains in its bioprocessing business. Along with its latest earnings reveal, Danaher also announced a notable executive shakeup, with a new CFO expected to take over next year and a new General Counsel already appointed. For the fiscal year 2025, ending in December 2025, Wall Street analysts expect a modest growth in Danaher's bottom line, forecasting a 3.9% YOY growth in its EPS to $7.77 on a diluted basis. The company has a mixed history of surpassing consensus estimates, topping them in three of the trailing four quarters and missing them on one occasion. Among the 23 analysts covering Danaher's stock, the consensus is a 'Strong Buy.' That's based on 19 'Strong Buy' ratings, one 'Moderate Buy' rating, and three 'Holds.' The configuration of the ratings appears slightly more bullish than two months ago, when the stock had 18 'Strong Buy' ratings. Highlighting confidence in the company's prospects amid current market conditions, Guggenheim analyst Subbu Nambi maintained a 'Buy' rating on Danaher's stock in late July and reiterated the $250 price target. Additionally, underscoring a positive outlook, Baird analyst Catherine Schulte reaffirmed the firm's 'Outperform' rating, while raising the price target on the stock from $226 to $229. Danaher's mean price target of $243.33 indicates a premium of 16.3% from the current market prices. The Street-high price target of $310 implies a potential upside of 48.2%. On the date of publication, Anushka Mukherjee did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
